Why Protalix BioTherapeutics, Inc.’s (PLX) Stock Is Up 5.17%
As of Thursday, October 15, Protalix BioTherapeutics, Inc.’s PLX share price has surged by 5.17%, which has investors questioning if this is right time to sell.Michael Rose
Stock Evaluator: Protalix BioTherapeutics, Inc. (PLX)
Protalix BioTherapeutics, Inc. PLX
$2.55
-0.02
-0.78%
October 23, 2026 4:00:00 PM
EST
Volume: 383,906
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
AMEX | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack, New Jersey.
Commentary & Analysis
Why Protalix BioTherapeutics, Inc.’s (PLX) Stock Is Down 5.43%
As of Thursday, October 01, Protalix BioTherapeutics, Inc.’s PLX share price has dipped by 5.43%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Protalix BioTherapeutics, Inc.’s (PLX) Stock Is Down 5.15%
As of Thursday, August 13, Protalix BioTherapeutics, Inc.’s PLX share price has dipped by 5.15%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Protalix BioTherapeutics, Inc.’s (PLX) Stock Is Up 8.02%
As of Wednesday, August 12, Protalix BioTherapeutics, Inc.’s PLX share price has surged by 8.02%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Protalix BioTherapeutics, Inc.’s (PLX) Stock Is Up 5.20%
As of Thursday, June 18, Protalix BioTherapeutics, Inc.’s PLX share price has surged by 5.20%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | PLX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $205.5 | $229.7 | 29% |
|
| Shares Out (Mil) | 82.6 | 53.4 | 58% |
|
| Institutional Ownership | 86.4% | 92.9% | 54% |
|
| Float (Mil) | 77.4 | 41.7 | 56% |
|
| Beta | 0.02 | 0.95 | 7% |
|
| Avg Daily Volume (000s) | 857 | 520 | 68% |
|
| Price Change (52-week) |
12.3% | 46.5% | 63% |
|
| Growth | PLX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (3.5%) | 13.2% | 11% |
|
| Net Income (5yr) | (0.3%) | (10.1%) | 40% |
|
| EPS (5yr) | 17.8% | 15.8% | 64 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (38.0%) | (15.7%) | 13% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | PLX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $81 | $37 | 24% |
|
| Net Income (TTM) (Mil) | $19 | ($44) | 49% |
|
| EPS (TTM) | $0.238 | ($1.600) | 48% |
|
| Operating Cash Flow (TTM) (Mil) | $10 | ($33) | 38% |
|
| Net Cash Flow (TTM) (Mil) | $10 | $2 | 56% |
|
| Long-Term Debt (Q1) (Mil) | $8 | $4 | 27% |
|
| Enterprise Value (Q1) (Mil) | $185 | $175 | 26% |
|
| Valuation | PLX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.87 | 2.17 | 66% |
|
| P/E | 10.8 | 20.1 | 21% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 0.6 | 1.1 | 31% |
|
| Ratios | PLX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 45.8% | 66.5% | 57% |
|
| Net Margin | 23.5% | (75.9%) | 82% |
|
| ROA | 20.1% | (47.2%) | 96% |
|
| ROE | 31.2% | (53.5%) | 88% |
|
| Liabilities to Assets | 35.3% | 29.4% | 26% |
|
| F-Score | 6 | 2 | 67% |
|
Passing Stock Screens
As of 10/23/2026, from a list of 60 stock screening strategies,
GURU STRATEGY
Magic Formula Screen
Factors: Value, Quality
Joel Greenblatt's investing approach is based on finding companies with high return on investment that are trading for less than they are worth.
| Performance Since Inception: | 7.0% |
| +/- S&P 500: | -0.5 |
